| Target Price | $1.02 |
| Price | $0.02 |
| Potential |
5,535.36%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Petros Pharmaceuticals Inc 2026 .
The average Petros Pharmaceuticals Inc target price is $1.02.
This is
5,535.36%
register free of charge
$1.05
5,701.10%
register free of charge
$1.01
5,480.11%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Petros Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Petros Pharmaceuticals Inc stock has an average upside potential 2026 of
5,535.36%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 5.11 | 5.59 |
| 12.20% | 9.30% | |
| Net Margin | -524.46% | -8.36% |
| 121.03% | 98.41% |
3 Analysts have issued a sales forecast Petros Pharmaceuticals Inc 2025 . The average Petros Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Petros Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Petros Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -83.46 | -1.11 |
| 47.41% | 98.67% | |
| P/E | negative | |
| EV/Sales | 0.77 |
3 Analysts have issued a Petros Pharmaceuticals Inc forecast for earnings per share. The average Petros Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Petros Pharmaceuticals Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


